

ACORDA - Walking Tall - Promise of Further Growth

<https://marketpublishers.com/r/A565E58054CEN.html>

Date: March 2012

Pages: 6

Price: US\$ 140.00 (Single User License)

ID: A565E58054CEN

Abstracts

Acorda (ACOR) has reached sustainable profitability through the sales of its marketed drug AMPYRA (dalfampridine, L, partnered with Biogen for EU, walking improvement in MS pts). We expect further growth in AMPRYA uptake in US (increased pt awareness), geographical expansion by partner Biogen and future label expansion in Cerebral Palsy and Chronic Stroke. Through acquisition and alliances, ACOR's diversification strategy (Pipeline beyond AMPYRA) should unfold successfully in coming years.. For more detail, please read our report released on 5th March, 2012 on Acorda titled "Walking Tall - Promise of Further Growth"

Contents

COMPANIES MENTIONED

Acorda

I would like to order

Product name: ACORDA - Walking Tall - Promise of Further Growth

Product link: <https://marketpublishers.com/r/A565E58054CEN.html>

Price: US\$ 140.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/A565E58054CEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970